A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.

Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M

Clinical endocrinology17 Oct 2007Cited by 52 (Europe PMC)

PMID17941902DOI10.1111/j.1365-2265.2007.03067.xPepBankPUB-17941902

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acromegaly, two patients had normal IGF-I during lanreotide but not octreotide.
In plain wordsIn acromegaly, two patients had normal IGF-I during lanreotide but not octreotide.
Peptide
Lanreotide
Outcome
Direction not reportedIGF-I normalized only during lanreotide
Study
n = 10
Comparator
Octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with IGF-I normalized only on this drug
2 patients
during LAN only
Patients with IGF-I normalized only on this drug
1 patients
during OCT only
Source sentences
Summary
Two patients on LAN and one on OCT had normalized IGF-I levels during one treatment and not during the other.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190207
02HumanRandomized controlled trialEfficacy outcome
In acromegaly, one patient had normal IGF-I during octreotide but not lanreotide.
In plain wordsIn acromegaly, one patient had normal IGF-I during octreotide but not lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedIGF-I normalized only during octreotide
Study
n = 10
Comparator
Lanreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with IGF-I normalized only on this drug
1 patients
during OCT only
Patients with IGF-I normalized only on this drug
2 patients
during LAN only
Source sentences
Summary
Two patients on LAN and one on OCT had normalized IGF-I levels during one treatment and not during the other.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190208
03HumanRandomized controlled trialSafety outcome
In acromegaly, three patients had gastrointestinal complaints only during lanreotide treatment.
In plain wordsIn acromegaly, three patients had digestive complaints with lanreotide but not octreotide.
Peptide
Lanreotide
Outcome
Direction not reportedGastrointestinal complaints only during lanreotide
Study
n: not reported in source
Comparator
Octreotide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with gastrointestinal complaints
3 patients
during both LAN and OCT
Patients with gastrointestinal complaints
3 patients
during LAN only
Patients with gastrointestinal complaints
1 patients
during OCT only
Source sentences
Summary
Gastrointestinal complaints were seen in three patients during both therapies, in three patients only during LAN, and in one patient only during OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190215
04HumanRandomized controlled trialSafety outcome
In acromegaly, one patient had gastrointestinal complaints only during octreotide treatment.
In plain wordsIn acromegaly, one patient had digestive complaints with octreotide but not lanreotide.
Peptide
Octreotide
Outcome
Direction not reportedGastrointestinal complaints only during octreotide
Study
n: not reported in source
Comparator
Lanreotide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with gastrointestinal complaints
3 patients
during both LAN and OCT
Patients with gastrointestinal complaints
3 patients
during LAN only
Patients with gastrointestinal complaints
1 patients
during OCT only
Source sentences
Summary
Gastrointestinal complaints were seen in three patients during both therapies, in three patients only during LAN, and in one patient only during OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190216
05HumanNon-randomized trialEfficacy outcome
In acromegaly, five patients had GH below 0.38 microg/l after six months of lanreotide.
In plain wordsIn acromegaly, five patients had GH below 0.38 microg/l after six months of lanreotide.
Peptide
Lanreotide
Outcome
Not applicableGH below threshold
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients below GH threshold
5 patients
reported result
GH threshold
< 0.38 microg/l
reported result
Source sentences
Summary
After 6 months of treatment, five patients had GH levels < 0.38 microg/l during both therapies.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190201
06HumanNon-randomized trialEfficacy outcome
In acromegaly, five patients had GH below 0.38 microg/l after six months of octreotide.
In plain wordsIn acromegaly, five patients had GH below 0.38 microg/l after six months of octreotide.
Peptide
Octreotide
Outcome
Not applicableGH below threshold
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients below GH threshold
5 patients
reported result
GH threshold
< 0.38 microg/l
reported result
Source sentences
Summary
After 6 months of treatment, five patients had GH levels < 0.38 microg/l during both therapies.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190202
07HumanNon-randomized trialEfficacy outcome
In acromegaly, the remaining patients had GH above 0.38 microg/l during lanreotide treatment.
In plain wordsIn acromegaly, the remaining patients had GH above 0.38 microg/l during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableGH above threshold
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
GH threshold
> 0.38 microg/l
remaining patients, during lanreotide
Source sentences
Summary
The remaining patients had GH levels > 0.38 microg/l during both LAN and OCT treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
After 6 months of treatment, five patients had GH levels < 0.38 microg/l during both therapies.
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190203
08HumanNon-randomized trialEfficacy outcome
In acromegaly, the remaining patients had GH above 0.38 microg/l during octreotide treatment.
In plain wordsIn acromegaly, the remaining patients had GH above 0.38 microg/l during octreotide treatment.
Peptide
Octreotide
Outcome
Not applicableGH above threshold
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
GH threshold
> 0.38 microg/l
remaining patients, during octreotide
Source sentences
Summary
The remaining patients had GH levels > 0.38 microg/l during both LAN and OCT treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
After 6 months of treatment, five patients had GH levels < 0.38 microg/l during both therapies.
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190204
09HumanNon-randomized trialEfficacy outcome
In acromegaly, four patients had normalized IGF-I during both lanreotide and octreotide treatment.
In plain wordsIn acromegaly, four patients had normal IGF-I during both lanreotide and octreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableIGF-I normalized during both regimens
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with normalized IGF-I during both regimens
4 patients
lanreotide and octreotide, 10 completers
Source sentences
Summary
Four patients had normalized IGF-I levels during both treatment regimes.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190205
10HumanNon-randomized trialEfficacy outcome
In acromegaly, four patients had normalized IGF-I during both octreotide and lanreotide treatment.
In plain wordsIn acromegaly, four patients had normal IGF-I during both octreotide and lanreotide treatment.
Peptide
Octreotide
Outcome
Not applicableIGF-I normalized during both regimens
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with IGF-I normalized during both treatments
4 patients
during both LAN and OCT
Source sentences
Summary
Four patients had normalized IGF-I levels during both treatment regimes.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190206
11HumanNon-randomized trialEfficacy outcome
In acromegaly, three patients had elevated IGF-I during both lanreotide and octreotide.
In plain wordsIn acromegaly, three patients had high IGF-I during both lanreotide and octreotide.
Peptide
Lanreotide
Outcome
Not applicablePersistently elevated IGF-I
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with persistently elevated IGF-I
3 patients
during both LAN and OCT
Source sentences
Summary
In three patients, IGF-I levels were elevated during both therapies.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190209
12HumanNon-randomized trialEfficacy outcome
In acromegaly, three patients had elevated IGF-I during both octreotide and lanreotide.
In plain wordsIn acromegaly, three patients had high IGF-I during both octreotide and lanreotide.
Peptide
Octreotide
Outcome
Not applicablePersistently elevated IGF-I
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with persistently elevated IGF-I
3 patients
during both LAN and OCT
Source sentences
Summary
In three patients, IGF-I levels were elevated during both therapies.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190210
13HumanNon-randomized trialOther
In acromegaly, four patients preferred lanreotide after the crossover study.
In plain wordsIn acromegaly, four patients preferred lanreotide after the study.
Peptide
Lanreotide
Outcome
Direction not reportedTreatment preference
Study
n = 10
Comparator
Octreotide
Outcome group
Treatment Preference · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients preferring lanreotide
4 patients
after both 6-month periods
Patients preferring the other drug
6 patients
after both 6-month periods
Source sentences
Summary
After the study period, four patients preferred LAN and six patients preferred OCT treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190218
14HumanNon-randomized trialOther
In acromegaly, six patients preferred octreotide after the crossover study.
In plain wordsIn acromegaly, six patients preferred octreotide after the study.
Peptide
Octreotide
Outcome
Direction not reportedTreatment preference
Study
n = 10
Comparator
Lanreotide
Outcome group
Treatment Preference · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients preferring octreotide
6 patients
after both 6-month periods
Patients preferring the other drug
4 patients
after both 6-month periods
Source sentences
Summary
After the study period, four patients preferred LAN and six patients preferred OCT treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190219
15HumanNon-randomized trialSafety outcome
In acromegaly, two patients developed palpable nodules during lanreotide treatment.
In plain wordsIn acromegaly, two patients developed nodules during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicablePalpable nodules
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with palpable nodules
2 patients
on LAN
Patients with palpable nodules
2 patients
on OCT
Patients with palpable nodules
4 patients
LAN and OCT combined
Source sentences
Summary
Four patients developed palpable nodules, two patients on LAN and two patients on OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190211
16HumanNon-randomized trialSafety outcome
In acromegaly, two patients developed palpable nodules during octreotide treatment.
In plain wordsIn acromegaly, two patients developed nodules during octreotide treatment.
Peptide
Octreotide
Outcome
Not applicablePalpable nodules
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with palpable nodules
2 patients
on LAN
Patients with palpable nodules
2 patients
on OCT
Patients with palpable nodules
4 patients
LAN and OCT combined
Source sentences
Summary
Four patients developed palpable nodules, two patients on LAN and two patients on OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190212
17HumanNon-randomized trialSafety outcome
In acromegaly, three patients had gastrointestinal complaints during both lanreotide and octreotide.
In plain wordsIn acromegaly, three patients had digestive complaints during both lanreotide and octreotide.
Peptide
Lanreotide
Outcome
Not applicableGastrointestinal complaints during both therapies
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with gastrointestinal complaints
3 patients
during both LAN and OCT
Patients with gastrointestinal complaints
3 patients
during LAN only
Patients with gastrointestinal complaints
1 patients
during OCT only
Source sentences
Summary
Gastrointestinal complaints were seen in three patients during both therapies, in three patients only during LAN, and in one patient only during OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190213
18HumanNon-randomized trialSafety outcome
In acromegaly, three patients had gastrointestinal complaints during both octreotide and lanreotide.
In plain wordsIn acromegaly, three patients had digestive complaints during both octreotide and lanreotide.
Peptide
Octreotide
Outcome
Not applicableGastrointestinal complaints during both therapies
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with gastrointestinal complaints
3 patients
during both LAN and OCT
Patients with gastrointestinal complaints
3 patients
during LAN only
Patients with gastrointestinal complaints
1 patients
during OCT only
Source sentences
Summary
Gastrointestinal complaints were seen in three patients during both therapies, in three patients only during LAN, and in one patient only during OCT.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190214
19HumanNon-randomized trialSafety outcome
In acromegaly, two patients withdrew because of serious adverse effects during lanreotide treatment.
In plain wordsIn acromegaly, two patients stopped the study because of serious adverse effects during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableWithdrawal due to serious adverse effects
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients withdrawn for serious adverse effects
2 patients
during LAN
Source sentences
Summary
Two patients were withdrawn from the study because of serious adverse effects during LAN.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
Report a problemFND-1794190217

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.

Summary

Results from this study19

Version history

Subjects

Publication types

MeSH terms